STERIS plc (NYSE:STE) Shares Purchased by Riverwater Partners LLC

Riverwater Partners LLC boosted its stake in shares of STERIS plc (NYSE:STE) by 21.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 4,847 shares of the medical equipment provider’s stock after acquiring an additional 864 shares during the period. Riverwater Partners LLC’s holdings in STERIS were worth $1,138,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in STE. Waldron Private Wealth LLC raised its position in shares of STERIS by 102.2% during the 3rd quarter. Waldron Private Wealth LLC now owns 2,346 shares of the medical equipment provider’s stock worth $569,000 after purchasing an additional 1,186 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of STERIS by 5.0% during the third quarter. Sequoia Financial Advisors LLC now owns 19,148 shares of the medical equipment provider’s stock valued at $4,644,000 after acquiring an additional 917 shares during the last quarter. Copeland Capital Management LLC lifted its position in shares of STERIS by 0.3% in the third quarter. Copeland Capital Management LLC now owns 223,570 shares of the medical equipment provider’s stock valued at $54,225,000 after acquiring an additional 772 shares in the last quarter. Suncoast Equity Management lifted its position in shares of STERIS by 5.2% in the third quarter. Suncoast Equity Management now owns 3,255 shares of the medical equipment provider’s stock valued at $789,000 after acquiring an additional 162 shares in the last quarter. Finally, Compass Ion Advisors LLC boosted its stake in shares of STERIS by 4.4% in the third quarter. Compass Ion Advisors LLC now owns 2,798 shares of the medical equipment provider’s stock worth $679,000 after acquiring an additional 118 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Stock Down 0.2 %

Shares of NYSE STE opened at $221.15 on Thursday. The company has a market capitalization of $21.81 billion, a P/E ratio of 54.88 and a beta of 0.84. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49. The company has a 50 day simple moving average of $234.99 and a 200-day simple moving average of $226.17. STERIS plc has a 1 year low of $195.47 and a 1 year high of $248.24.

STERIS (NYSE:STE) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.16. The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. STERIS’s revenue was down .4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.00 earnings per share. On average, equities research analysts predict that STERIS plc will post 9.06 earnings per share for the current year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, September 5th were paid a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, September 5th. This is a positive change from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 1.03%. STERIS’s dividend payout ratio is 56.58%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research reports. KeyCorp raised their price objective on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. JMP Securities reissued a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Monday. Stephens reissued an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $246.00.

Insider Transactions at STERIS

In related news, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now directly owns 582 shares of the company’s stock, valued at approximately $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.